191 related articles for article (PubMed ID: 21750216)
21. Gene-specific repair of Pt/DNA lesions and induction of apoptosis by the oral platinum drug JM216 in three human ovarian carcinoma cell lines sensitive and resistant to cisplatin.
O'Neill CF; Koberle B; Masters JR; Kelland LR
Br J Cancer; 1999 Dec; 81(8):1294-303. PubMed ID: 10604725
[TBL] [Abstract][Full Text] [Related]
22. Specificity of platinum-DNA adduct repair.
Chaney SG; Vaisman A
J Inorg Biochem; 1999 Oct; 77(1-2):71-81. PubMed ID: 10626357
[TBL] [Abstract][Full Text] [Related]
23. Transcription inhibition by platinum-DNA cross-links in live mammalian cells.
Ang WH; Myint M; Lippard SJ
J Am Chem Soc; 2010 Jun; 132(21):7429-35. PubMed ID: 20443565
[TBL] [Abstract][Full Text] [Related]
24. Human colon cancer cells surviving high doses of cisplatin or oxaliplatin in vitro are not defective in DNA mismatch repair proteins.
Sergent C; Franco N; Chapusot C; Lizard-Nacol S; Isambert N; Correia M; Chauffert B
Cancer Chemother Pharmacol; 2002 Jun; 49(6):445-52. PubMed ID: 12107548
[TBL] [Abstract][Full Text] [Related]
25. Organic cation transporters are determinants of oxaliplatin cytotoxicity.
Zhang S; Lovejoy KS; Shima JE; Lagpacan LL; Shu Y; Lapuk A; Chen Y; Komori T; Gray JW; Chen X; Lippard SJ; Giacomini KM
Cancer Res; 2006 Sep; 66(17):8847-57. PubMed ID: 16951202
[TBL] [Abstract][Full Text] [Related]
26. East-west fusion-necrosis and apoptosis acting in concert by demethylcantharidin-integrated platinum complexes.
Pang SK; So WK; Ho YP; Au-Yeung CF
Anticancer Agents Med Chem; 2014 Jun; 14(5):756-61. PubMed ID: 24476313
[TBL] [Abstract][Full Text] [Related]
27. Mechanistic added value of a trans-Sulfonamide-Platinum-Complex in human melanoma cell lines and synergism with cis-Platin.
Agudo-López A; Prieto-García E; Alemán J; Pérez C; Díaz-García CV; Parrilla-Rubio L; Cabrera S; Navarro-Ranninger C; Cortés-Funes H; López-Martín JA; Agulló-Ortuño MT
Mol Cancer; 2017 Feb; 16(1):45. PubMed ID: 28231799
[TBL] [Abstract][Full Text] [Related]
28. Role of p21waf1/cip1 in effects of oxaliplatin in colorectal cancer cells.
Hata T; Yamamoto H; Ngan CY; Koi M; Takagi A; Damdinsuren B; Yasui M; Fujie Y; Matsuzaki T; Hemmi H; Xu X; Kitani K; Seki Y; Takemasa I; Ikeda M; Sekimoto M; Matsuura N; Monden M
Mol Cancer Ther; 2005 Oct; 4(10):1585-94. PubMed ID: 16227409
[TBL] [Abstract][Full Text] [Related]
29. Reactivating p53 and Inducing Tumor Apoptosis (RITA) Enhances the Response of RITA-Sensitive Colorectal Cancer Cells to Chemotherapeutic Agents 5-Fluorouracil and Oxaliplatin.
Wiegering A; Matthes N; Mühling B; Koospal M; Quenzer A; Peter S; Germer CT; Linnebacher M; Otto C
Neoplasia; 2017 Apr; 19(4):301-309. PubMed ID: 28284059
[TBL] [Abstract][Full Text] [Related]
30. The monofunctional platinum(II) compounds, phenanthriplatin and pyriplatin, modulate apoptosis signaling pathways in HEI-OC1 auditory hybridoma cells.
Monroe JD; Johnston AM; Smith ME
Neurotoxicology; 2020 Jul; 79():104-109. PubMed ID: 32413439
[TBL] [Abstract][Full Text] [Related]
31. Mechanism of trifluorothymidine potentiation of oxaliplatin-induced cytotoxicity to colorectal cancer cells.
Temmink OH; Hoebe EK; van der Born K; Ackland SP; Fukushima M; Peters GJ
Br J Cancer; 2007 Jan; 96(2):231-40. PubMed ID: 17242697
[TBL] [Abstract][Full Text] [Related]
32. Role of endonucleases XPF and XPG in nucleotide excision repair of platinated DNA and cisplatin/oxaliplatin cytotoxicity.
Graf N; Ang WH; Zhu G; Myint M; Lippard SJ
Chembiochem; 2011 May; 12(7):1115-23. PubMed ID: 21452186
[TBL] [Abstract][Full Text] [Related]
33. Cell-cycle inhibition and apoptosis induced by curcumin and cisplatin or oxaliplatin in human ovarian carcinoma cells.
Montopoli M; Ragazzi E; Froldi G; Caparrotta L
Cell Prolif; 2009 Apr; 42(2):195-206. PubMed ID: 19236381
[TBL] [Abstract][Full Text] [Related]
34. Protein interactions with platinum-DNA adducts: from structure to function.
Chaney SG; Campbell SL; Temple B; Bassett E; Wu Y; Faldu M
J Inorg Biochem; 2004 Oct; 98(10):1551-9. PubMed ID: 15458816
[TBL] [Abstract][Full Text] [Related]
35. Cellular and molecular pharmacology of oxaliplatin.
Raymond E; Faivre S; Chaney S; Woynarowski J; Cvitkovic E
Mol Cancer Ther; 2002 Jan; 1(3):227-35. PubMed ID: 12467217
[TBL] [Abstract][Full Text] [Related]
36. Differential transport of platinum compounds by the human organic cation transporter hOCT2 (hSLC22A2).
Burger H; Zoumaro-Djayoon A; Boersma AW; Helleman J; Berns EM; Mathijssen RH; Loos WJ; Wiemer EA
Br J Pharmacol; 2010 Feb; 159(4):898-908. PubMed ID: 20067471
[TBL] [Abstract][Full Text] [Related]
37. Oxaliplatin-induced gamma-H2AX activation via both p53-dependent and -independent pathways but is not associated with cell cycle arrest in human colorectal cancer cells.
Chiu SJ; Lee YJ; Hsu TS; Chen WS
Chem Biol Interact; 2009 Dec; 182(2-3):173-82. PubMed ID: 19735649
[TBL] [Abstract][Full Text] [Related]
38. Efficient nucleotide excision repair of cisplatin, oxaliplatin, and Bis-aceto-ammine-dichloro-cyclohexylamine-platinum(IV) (JM216) platinum intrastrand DNA diadducts.
Reardon JT; Vaisman A; Chaney SG; Sancar A
Cancer Res; 1999 Aug; 59(16):3968-71. PubMed ID: 10463593
[TBL] [Abstract][Full Text] [Related]
39. Effect of p53 status on sensitivity to platinum complexes in a human ovarian cancer cell line.
Pestell KE; Hobbs SM; Titley JC; Kelland LR; Walton MI
Mol Pharmacol; 2000 Mar; 57(3):503-11. PubMed ID: 10692490
[TBL] [Abstract][Full Text] [Related]
40. DNA damage inducible-gene expression following platinum treatment in human ovarian carcinoma cell lines.
Delmastro DA; Li J; Vaisman A; Solle M; Chaney SG
Cancer Chemother Pharmacol; 1997; 39(3):245-53. PubMed ID: 8996528
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
